Biopol Chemicals Ltd
Incorporated in 2023, Biopol Chemicals Ltd is engaged in the business of Trading and Manufacturing of Speciality Chemicals[1]
- Market Cap ₹ 47.3 Cr.
- Current Price ₹ 43.8
- High / Low ₹ 134 / 39.5
- Stock P/E 5.27
- Book Value ₹ 46.2
- Dividend Yield 0.00 %
- ROCE 34.1 %
- ROE 28.2 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.95 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 25.42 | 49.22 | 81.14 | |
| Sales growth | +93.63% | +64.85% | |
| 20.99 | 42.67 | 67.69 | |
| Operating Profit | 4.43 | 6.55 | 13.45 |
| OPM % | 17.43% | 13.31% | 16.58% |
| 0.00 | 0.00 | 0.23 | |
| Interest | 0.39 | 0.68 | 1.52 |
| Depreciation | 0.08 | 0.09 | 0.10 |
| Profit before tax | 3.96 | 5.78 | 12.06 |
| Tax % | 25.25% | 25.43% | 25.62% |
| 2.96 | 4.31 | 8.97 | |
| EPS in Rs | 3.74 | 5.45 | 8.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 65% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 108% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| Last Year: | 28% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 7.91 | 7.91 | 10.81 |
| Reserves | 1.29 | 5.68 | 39.12 |
| 3.58 | 7.68 | 8.46 | |
| 4.77 | 10.40 | 11.38 | |
| Total Liabilities | 17.55 | 31.67 | 69.77 |
| 0.21 | 0.25 | 14.36 | |
| CWIP | 0.06 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 17.28 | 31.42 | 55.41 | |
| Total Assets | 17.55 | 31.67 | 69.77 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -6.44 | -2.41 | -12.77 | |
| -0.64 | -0.02 | -14.53 | |
| 7.14 | 3.50 | 26.67 | |
| Net Cash Flow | 0.06 | 1.07 | -0.63 |
| Free Cash Flow | -6.53 | -2.43 | -26.97 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -141% | -30% | -93% |
Ratios
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 145.45 | 123.55 | 125.01 |
| Inventory Days | 121.21 | 106.99 | 113.43 |
| Days Payable | 77.90 | 77.91 | 37.25 |
| Cash Conversion Cycle | 188.76 | 152.63 | 201.19 |
| Working Capital Days | 127.36 | 94.99 | 178.86 |
| ROCE % | 37.94% | 34.09% |
Documents
Announcements
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
- Biopol Chemicals says Corporate Governance Report not applicable for Q2 and half year ended September 30, 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter and half-year ended September 30, 2026.
-
Trading Window
- Trading window closes from October 1, 2026 until 48 hours after half-year results disclosure.
-
Shareholders meeting
- 3rd AGM voting results: all 4 resolutions passed on 22 Sept 2026, including financials, director reappointment and RPTs.
-
General Updates
- AGM regularised Sukhomoy Das as Independent Director for five years from June 11, 2026.
Business Overview:[1]
BCL is engaged in manufacturing and distribution of specialty chemicals across four 4 categories, namely silicones, emulsifiers, biochemicals and polyelectrolytes.
The company also provides technical consultancy services to customers, including support in specialty chemical applications, textile processing, dye manufacturing and industrial formulations.